October 13, 2022 C-Path’s Transplant Therapeutics Consortium Receives EMA Draft Qualification Opinion for iBox Scoring System The draft EMA qualification opinion is available for public consultation until November 17, 2022 Secondary endpoint prognostic for
October 6, 2022 C-Path to Lead Pre-Consortium Aimed at Transforming, Accelerating Medical Product Development in Alpha-1 Antitrypsin Deficiency TUCSON, Ariz., Oct. 6, 2022 — Critical Path Institute (C-Path) today announced that it has recently launched a pre-consortium co
October 1, 2022 Perspectives on Drug Development in Autosomal Recessive Polycystic Kidney Disease Autosomal recessive polycystic kidney disease (ARPKD) is a rare hepatorenal fibrocystic disease that often presents prenatally
October 1, 2022 Perspectives on Drug Development in Early ADPKD The Critical Path Institute’s Polycystic Disease Outcomes Consortium, including key stakeholders (patients, medical experts
September 29, 2022 eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Evaluating the Use of Backup Solutions for ePRO Systems” has been publ
September 27, 2022 Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation Board names Dr. Daniel Jorgensen as Chief Executive Officer TUCSON, Ariz., Sept. 27, 2022 — Critical Path Institute (C-Path) tod
September 22, 2022 View Now: Workshop: Accelerating Medical Product Development in Kidney Transplantation Through a Public-private Partnership C-Path’s Transplant Therapeutics Consortium (TTC), in collaboration with key opinion leaders from academic institutions, the pha
September 21, 2022 Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports
September 20, 2022 C-Path’s European Nonprofit Appoints Managing Director and New Board Member to Expand Global Efforts TUCSON, Ariz. and AMSTERDAM, September 20, 2022 — Critical Path Institute’s (C-Path) European nonprofit today announced the ap
